JAZZ: Jazz Pharmaceuticals plc - Summary | Jitta

Jazz Pharmaceuticals plc

NASDAQ:JAZZ

Price
$168.65
Loss Chance
42.9%
6.14JITTA SCORE
61.48%Under Jitta Line
Jitta Ranking
15 / 936
279 / 4,286
Grow your money with Jitta Ranking. See details.
HISTORICAL JITTA SCORE
Jitta Factors
Growth Opportunity (61)
Recent Business Performance (27)
Financial Strength (88)
Return to Shareholders (59)
Competitive Advantage (64)
Jitta Signs
Revenue and EarningConsistent Growth in the past 5 years
Recent Business PerformanceEarning Growth Last Year
Debt LevelLow Long Term Debt
Return on EquityConsistently High
Share RepurchaseEvery Year
CapExVery Low
Interest Coverage RatioVery Good
Operating MarginDeclined
Key Stats
Jitta Score
Jitta Line
6.14
61.48%
2.13
157.16%
2.30
340.45%
Pharmaceuticals
6.17
52.18%
3.80
45.34%
7.54
7.75%
COMPANY DESCRIPTION
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various unmet medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of neuroscience, including sleep medicine and movement disorders; and in oncology, including hematologic and solid tumors. Its lead marketed products include Xyrem, an oral solution for the treatment of cataplexy and excessive daytime sleepiness (EDS) in adult and pediatric patients with narcolepsy; Sunosi for the treatment of EDS in patients with narcolepsy and obstructive sleep apnea; Erwinaze to treat acute lymphoblastic leukemia; Defitelio for the treatment of adult and pediatric patients with hepatic veno-occlusive disease; and Vyxeos liposome for injection, a product for the treatment of adults with newly-diagnosed therapy-related acute myeloid leukemia. The company also offers JZP-258, an oxybate product candidate, to treat EDS and cataplexy with narcolepsy and idiopathic hypersomnia; JZP-324, a low sodium oxybate formulation with the potential to provide a clinically meaningful option for some narcolepsy patients; JZP-385, a T-type calcium channel modulator, for the treatment of essential tremor; JZP-458, a recombinant Erwinia asparaginase, for use as a component of a multi-agent chemotherapeutic regimen in the treatment of pediatric and adult patients; and lurbinectedin, a product candidate under clinical investigation for the treatment of patients with relapsed small cell lung cancer. Jazz Pharmaceuticals plc has licensing and collaboration agreements with ImmunoGen, Inc.; Codiak BioSciences, Inc.; Pfenex, Inc.; XL-protein GmbH; and Redx Pharma plc . The company was founded in 2003 and is headquartered in Dublin, Ireland.